We have the largest, deepest,

ex-vivo gene therapy
data set in the world.


clinical and pre-clinical research
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • PH 3 

    SCD (HGB-210)

  • PH 1/2 

    SCD (HGB-206)

  • PH 1 

    Sickle Cell Disease

  • PRE-C 


The lovo-cel clinical program is currently on a partial clinical hold pertaining to pediatric patients (under 18) related to an adolescent patient with persistent, non-transfusion-dependent anemia. bluebird bio, Inc. continues to work with the FDA to resolve the partial hold.

bluebird bio, Inc. gene therapy for sickle cell disease is investigational and not FDA-approved. Safety and efficacy have not been established.